Cancer Family
Cutaneous Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000153Explore in graph →
HematologicNon-malignant69 active trials10 approved drugs
- NCIt
- C45240
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000153Explore in graph →
Clinical trials
371 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02883517 | Cell-free Circulating DNA in Primary Cutaneous Lymphomas(MATULILA) | completed | — | 35 | University Hospital, BordeauxOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT02689453 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2022 |
| clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04955340 | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | completed | Phase 1 | 5 | 4SC AGINDUSTRY | 1 | Feb 18, 2022 | clinicaltrials |
| NCT01445535 | Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00425555 | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma | completed | Phase 2 | 139 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 20, 2021 | clinicaltrials |
| NCT02676778 | Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma | completed | Phase 2 | 45 | Eisai Co., Ltd.INDUSTRY | 1 | Jul 15, 2021 | clinicaltrials |
| NCT04171791 | A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) | completed | Phase 1 | 4 | Yale UniversityOTHER | 1 | Jun 25, 2021 | clinicaltrials |
| NCT03239392 | A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | completed | Phase 1 / Phase 2 | 50 | Bioniz TherapeuticsINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT02037256 | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma | completed | N/A | 23 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT03292406 | A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)(CTCL) | completed | Phase 2 | 86 | Galderma R&DINDUSTRY | 3 | Apr 8, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT02593045 | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | completed | Phase 1 | 44 | Innate PharmaINDUSTRY | 4 | Jan 20, 2021 | clinicaltrials |
| NCT04702503 | Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 1 | 5 | Moleculin Biotech, Inc.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)(ALCANZA) | completed | Phase 3 | 131 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Jan 5, 2021 | clinicaltrials |
| NCT02580552 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | completed | Phase 1 | 66 | miRagen Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00744991 | A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma | completed | Phase 2 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02761473 | Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations | completed | — | 50 | University of MinnesotaOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02296164 | Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma(PROVe) | completed | — | 300 | Helsinn Therapeutics (U.S.), IncINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01239875 | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | completed | Early Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT00554827 | Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | completed | Phase 1 | 55 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 3, 2020 | clinicaltrials |
| NCT00003196 | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | completed | N/A | 63 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 27, 2019 | clinicaltrials |
| NCT01134341 | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | completed | Phase 1 | 34 | Acrotech Biopharma Inc.INDUSTRY | 2 | Dec 18, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02652715 | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | completed | N/A | 29 | Mayo ClinicOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00856388 | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | completed | N/A | 62 | Roswell Park Cancer InstituteOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 4 | 59 | Bausch Health Americas, Inc.INDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00106431 | A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) | completed | Phase 2 | 102 | CelgeneINDUSTRY | 6 | Oct 30, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT00005799 | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | N/A | 55 | Fred Hutchinson Cancer CenterOTHER | 2 | Sep 10, 2019 | clinicaltrials |
| NCT02822586 | TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome | completed | Phase 1 | 5 | Virginia Commonwealth UniversityOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01676831 | Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) | completed | Phase 1 / Phase 2 | 13 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03632811 | Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language(Mc_QoL) | completed | — | 30 | University Hospital, ToulouseOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT01800838 | Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 11 | Kevin Cooper MDOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT00038025 | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT00038376 | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01590732 | Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma | completed | Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
Data updated 22 days agoSource updated May 13, 2022source: clinicaltrials